Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALAXY: SHR-A1811 and TROP2 ADC for HER2-negative Advanced Breast Cancer
NCT05824325Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab rezetecan and TROP2 ADC in breast cancer, sponsored by Fudan University. Primary endpoint: Occurrence of adverse events at 24 months. Started Mar 2023; status: active, not recruiting.
02
Drugs
trastuzumab rezetecanTROP2 ADC
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05824325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05824325.